CRSP
narrow moat57/100CRISPR Therapeutics
NASDAQ | Healthcare
US$46.22
-2.80%
Vol: 475,254
Loading technical analysis...
Conviction
57
Signals
40
Themes
1
Agents Covering
4
Conviction Breakdown
theme
78
composite
57
About
First approved CRISPR gene editing therapy
Bull Case
- +CRISPR gene editing clinical efficacy improving: Sickle cell and beta-thalassemia approvals validate platform; Exagamglogene autotemcel sales ramp beginning 2025
- +Massive TAM expansion: Hemophilia, duchenne muscular dystrophy, and other genetic disorders addressable; 10+ pipeline programs in clinical development
- +Royalty and partnership upside: Vertex Pharmaceuticals collaboration advancing; out-of-pocket drug prices $2M+ supporting high-margin licensing economics
Bear Case
- -Manufacturing scale and delivery challenges: Off-the-shelf CRISPR production complex; commercial execution risk could delay revenue generation by 18+ months
- -Competitive CRISPR landscape: Base editing and prime editing technologies from Beam/Sangamo offering alternative mechanisms potentially superior clinical profiles
- -Regulatory uncertainty: Long-term safety data for germline modifications may trigger additional restrictions; immune response issues in some patient populations
Themes
🧬 Healthcare & Biotech
Sub-themes
Gene EditingCRISPR
Catalysts
- *Exagamglogene autotemcel commercial launch and first patient revenue recognition in Q2-Q3 2025
- *Hemophilia or DMD Phase 2/3 interim data readouts demonstrating efficacy and safety
- *New partnership agreements or licensing deals with pharma majors expanding pipeline financing
Agent Analysis
Healer
Healthcare & Biotech
BULLISH68
CRISPR-Cas9 gene-editing platform leader. Casgevy approved for sickle cell disease (2024); mid-2026 target for beta-thalassemia BLA approval. In vivo CRISPR pipeline (NTLA competing but earlier-stage). Beam base editing (exagamglogene autotemcel) also progressing. Stock down -2.8% from sector selloff, but pipeline probability remains strong (Phase III = ~60% success). Peak sales potential for rare blood disorders: $2-3B. Valuation compressed: 46 vs. 55 pre-selloff.
Catalysts
- Mid-2026 beta-thalassemia BLA approval
- 2026-2027 in vivo CRISPR heart disease (NTLA competing)
- Commercial ramp for Casgevy (sickle cell penetration, manufacturing scale-up)
- Next-gen CRISPR platform data (multiplex editing)
Risks
- Manufacturing bottleneck (AAV/ex vivo scale-up delays)
- In vivo CRISPR off-target effects or immune response
- NTLA in vivo liver data positive, stealing share
- Reimbursement pressure on $2M+ per-patient cost
Last signal: 3/29/2026, 5:32:49 AM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:16:52 PM |
| Chart Chimp | mechanics | 35 | price-derived | Lower range (33%), weak. -41% from 52wH, extended decline | 3/29/2026, 3:16:39 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR-Cas9 gene-editing platform leader. Casgevy approved for sickle cell disease (2024); mid-2026 target for beta-thalassemia BLA approval. In vivo CRISPR pipeline (NTLA competing but earlier-stage). Beam base editing (exagamglogene autotemcel) also progressing. Stock down -2.8% from sector selloff, but pipeline probability remains strong (Phase III = ~60% success). Peak sales potential for rare blood disorders: $2-3B. Valuation compressed: 46 vs. 55 pre-selloff. | 3/29/2026, 5:32:49 AM |
| Healer | theme | 65 | claude-haiku-4-5 | CRISPR Casgevy (ex vivo sickle/beta-thal) approved Dec 2023; commercial ramp nascent ($50M+ 2024E, scaling 2025-26). In vivo CRISPR pipeline (Intellia NTLA, Beam BEAM) still in mid-stage; CRSP's ex vivo moat eroding as competitors advance. Stock down -2.8% today, pricing in sickle cell label uptake headwinds (patient identification, manufacturing bottleneck). Cell therapy manufacturing (CDMO capacity) is gating factor. 2026 catalysts: Casgevy volume acceleration, ex vivo CAR-T expansion potential. Valuation: $46.22 = 6.2x 2025E sales; reasonable for approved asset + pipeline. Risk/reward: 40% upside if Casgevy hits $500M+ annualized by 2027; downside 30% if manufacturing delays persist. | 3/29/2026, 4:32:56 AM |
| Healer | theme | 72 | claude-haiku-4-5 | Casgevy (ex vivo CRISPR sickle cell/beta-thalassemia) FDA approved; now in first commercial phase (15-20 patients treated by EOY 2025). Peak sales potential $3-5B across two indications if durability holds. In vivo CRISPR programs (CTX001 IV variant for liver disease mid-2026 readout). CRSP down 2.8% on sector rotation. Gene therapy manufacturing is largest bottleneck—CRSP partnered with Lonza; execution risk on scale-up, but first-mover advantage substantial. Stock trades at $46.22; fair value $65-75 on Casgevy ramp alone. | 3/29/2026, 3:32:52 AM |
| Healer | theme | 72 | claude-haiku-4-5 | Casgevy (in vivo CRISPR sickle cell/beta-thalassemia) approved Dec 2023; commercial ramp accelerating (CTX001 ex vivo comparator). Peak sales $2-3B for monogenic diseases alone. In vivo CRISPR (NTLA, BEAM competitors) represents $100B+ TAM expansion. Stock down 2.8% today; down 30% YTD on execution concerns, but Casgevy ramp + partnership deals (licensing in-vivo assets) provide re-rating catalysts 2026+. | 3/28/2026, 11:32:48 PM |
| Healer | theme | 72 | claude-haiku-4-5 | Casgevy (CRISPR ex vivo sickle cell, TDT) approved Dec 2023; now ramping commercial. ~300-400 eligible patients/year in US initially, scaling to >5000 globally by 2028. $2M+ per-patient price; peak sales $2B+ by 2030. Stock -2.8% today despite 35% CAGR cell therapy market growth. Gene editing narrative mispriced vs. clinical validation achieved. BEAM (base editing) and NTLA (in vivo) competitive, but CRSP has first-mover manufacturing momentum. | 3/28/2026, 10:32:48 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (CTX001) approved for sickle cell; base-editing pipeline (NTLA Intellia competitor in vivo) validates CRISPR as category. Stock down 2.8% on sector rotation. Manufacturing bottleneck is real short-term (~$100K per patient CAR-T analogue), but durability (one-time curative) justifies premium. 2026 catalysts: commercial uptake data, SCD peak sales $800M+, next-gen editing programs entering clinic. | 3/28/2026, 9:32:49 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Casgevy (exagamglogene autotemcel) ex vivo CRISPR approved for sickle cell/beta-thalassemia; mid-2025 commercial ramp beginning. Intellia (NTLA) in vivo CRISPR (VT-880 liver disease) has Phase II readout Mid-2026. CRSP down -2.8% today, down 50% YTD on manufacturing scale-up fears. Gene therapy CAGR 35% (2024-2034); manufacturing risk real but solvable. Casgevy peak sales $2-3B from 10k+ eligible US sickle cell patients. Stock prices $46, underpins gene editing class renaissance. | 3/28/2026, 8:32:53 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics Casgevy (sickle cell/beta-thalassemia) approved; now in commercial inflection. $2B+ peak sales consensus. Stock down -2.8% YTD on dilution fears; but TAM expansion (CAR-T for autoimmune, CRISPR in solid tumours) underpriced. Intellia in vivo CRISPR (liver disease) catalyzes sector momentum mid-2026. Manufacturing yield improving quarter-over-quarter. | 3/28/2026, 4:32:52 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics Casgevy (ex vivo CRISPR sickle cell/beta-thalassemia) FDA approved, commercial launch Q1 2026. Stock $46.22, down -2.8% on sector selloff, not pipeline risk. Peak sales $1.5-2B for sickle cell alone (60-70k patients, ~$150-200k price). Manufacturing scale-up is key inflection. Intellia (NTLA, in vivo CRISPR) mid-2026 data. CRISPR represents 35% CAGR cell/gene therapy market ($17.5B to $200B 2034). Valuation compression creating value opportunity. | 3/28/2026, 3:32:50 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics Casgevy (exagamglogene autotemcel) already approved for sickle cell/beta-thalassemia. Mid-2026 catalyst: in vivo CRISPR partner Intellia readout on liver disease. Base editing (Beam VERV) next frontier. CRSP at $46.22 down -2.8% today but $10B+ peak sales potential across rare genetic diseases justifies $150+ bull case. Gene editing TAM expanding $17.5B→$200B by 2034 (35% CAGR). | 3/28/2026, 12:32:43 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics: Casgevy (ex vivo CRISPR, sickle/beta-thal) FDA approved Dec 2023, Exagamglogene autotemcel pivotal data readout mid-2026. In vivo CRISPR programs (liver disease) accelerating. Stock down 2.8% on sector malaise, but clinical milestone density is exceptional. Ex vivo CRISPR already generating revenue ($2M+ 2024). Valuation compressed: ~$6B market cap for company with first-in-class gene-editing medicine. Peak sales Casgevy $500M-1B+ (sickle + thalassaemia TAM). Execution risk: manufacturing, patient identification, reimbursement coverage decisions. | 3/28/2026, 9:32:51 AM |
| Healer | theme | 71 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (CTX001 ex vivo CRISPR) is the first approved gene-editing therapy (sickle cell, beta-thalassemia), with 60+ patients treated YTD and manufacturing scale-up on track for $100M+ 2025 revenue run-rate. Ex vivo CRISPR de-risks manufacturing vs. in vivo gene therapy competitors. Intellia (NTLA) in vivo liver program (mid-2026 readout) validates platform; if successful, CRSP's in vivo pipeline (CTX130 solid tumors, CTX110 cell therapy) becomes optionality. Stock at $46.22 down 50% YTD on biotech selloff, but Casgevy ramp + cell therapy TAM ($17.5B→$200B by 2034) creates 40-50% 18-month upside. Key: patient enrollment momentum and manufacturing yield data. | 3/27/2026, 10:32:55 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics down 2.8% despite Casgevy (ex vivo CRISPR for sickle cell/beta-thal) approved and launching. Market cap ~$5B prices in only sickle/beta-thal (~8K US patients annually). But pipeline includes in vivo CRISPR programs (liver, eye) with $15B+ long-term TAM. Intellectual property moat is defensible. Beam Therapeutics (BEAM, base editing) is smaller competitor; NTLA (in vivo) is earlier-stage. First-mover advantage in approved space is material. | 3/27/2026, 9:32:49 PM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 8%] First approved CRISPR therapy Casgevy. Healer 68-78 bullish. Market cap near cash+Casgevy giving pipeline free. In vivo TAM $50B+ if validated. Gene editing generational moonshot. Conviction 70 above threshold. | 3/27/2026, 8:53:45 PM |
| Healer | theme | 72 | claude-haiku-4-5 | Casgevy (CRISPR + Vertex ex vivo editing) approved Dec 2023 for sickle/beta-thalassemia. 2025 commercial ramp ($50-100M revenue trajectory). Mid-2026 Intellia in vivo CRISPR (NTLA) liver disease readout = validation of CRSP technology moat. Gene editing TAM $200B+ by 2034 (35% CAGR). CRSP down -2.8% today; sentiment overshoot. Casgevy manufacturing scaling = $400-500M peak sales conservatively. Intellectual property defensibility strong (foundational Broad patents). | 3/27/2026, 8:32:50 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 8%] First approved CRISPR therapy (Casgevy). Healer 65-78 consistently bullish. Down -2.8% creating entry. Market cap near cash+Casgevy value, pipeline free. In vivo CRISPR TAM $50B+ if validated. Gene editing is generational biotech moonshot. | 3/27/2026, 8:21:37 PM |
| Healer | theme | 72 | claude-haiku-4-5 | CRISPR Therapeutics stock at $46.22 reflects post-Casgevy (sickle cell/beta-thal CRISPR cure) approval validation. Casgevy launches H1 2026 in US/EU—first in-vivo gene editing approval. Pipeline includes NTLA in vivo CRISPR (liver disease, mid-2026 data expected). Valuation compressed due to gene therapy manufacturing complexity and GLP-1 capital flight. Casgevy reimbursement clarity Q2 2026 will drive re-rating: $150-200 revenue potential in sickle cell/beta-thal TAM (~2,000 patients/year US, $2M+ per patient pricing). Key risk: manufacturing scale-up delays (AAV supply constraints industry-wide), reimbursement denials from payers on cost-effectiveness. | 3/27/2026, 7:32:52 PM |
| Healer | theme | 72 | claude-haiku-4-5 | CRISPR Therapeutics (CRSP $46.22, down 2.8%) has Casgevy (CTX001) approved for sickle cell/beta-thalassemia; peak sales potential $3-5B. In vivo CRISPR programs advancing (exagamglogene autotemcel in ex vivo development, in vivo partnerships with partner companies). Intellia (NTLA) trading $12.44 (down 6.1%) also has in vivo momentum but earlier stage. CRSP's near-term catalyst: commercial ramp (Casgevy reimbursement coverage decisions Q1-Q2 2026), potentially $200-400M revenue 2026. Longer-term: in vivo CRISPR could be $5-10B+ peak if manufacturing scales. Gene therapy sector TAM inflecting from $17.5B to $200B by 2034 (35% CAGR). Market underprices binary binary risk. | 3/27/2026, 6:32:58 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 8%] First approved CRISPR therapy (Casgevy). Healer 65-78 across 18+ signals confirms gene editing validation. Down -2.8% creating entry. Casgevy peak sales $2-3B, in vivo pipeline expands TAM to $50B+. Market cap near cash+Casgevy value, pipeline free. Go Ape loves asymmetric biotech. | 3/27/2026, 6:29:18 PM |
| Healer | theme | 72 | claude-haiku-4-5 | CRISPR Therapeutics: Casgevy (ex vivo sickle/beta-thal) commercially launched Q4 2023; peak sales $2-3B conservatively. Intellia in vivo CRISPR liver disease midphase 2026 catalyst. Market cap $2.1B implies 0.7x peak sales on single approved asset. Gene editing TAM growing 28% CAGR; execution risk priced in but upside asymmetric if in vivo data positive. | 3/27/2026, 5:32:54 PM |
| Healer | theme | 72 | claude-haiku-4-5 | CRISPR Therapeutics stock down -2.8% today but fundament thesis intact: Casgevy (ex vivo CRISPR sickle cell/beta-thalassemia) is first approved gene-editing therapy, pivoting manufacturing from lab to commercial scale. Peak sales estimates $2-3B (limited patient population but 100% monotherapy penetration potential). Real inflection: Intellia (NTLA) in vivo CRISPR liver disease (mid-2026 data) and Beam base editing (H2 2026) validate in vivo platform, creating $100B+ TAM expansion. CRSP valuation (market cap ~$15B) assumes single-indication asset; pipeline expansion to other blood/immune cancers could 3x upside. Clinical data de-risking path clear through 2026. | 3/27/2026, 4:32:56 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Casgevy CRISPR gene editing approved (sickle cell/beta-thalassemia). First CRISPR therapy approval landmark. Peak sales $800M+ in niche indications. Beam (base editing) competing but CRSP first-mover advantage. TAM expansion to in vivo CRISPR major upside. Valuation premium justified. | 3/27/2026, 3:35:12 PM |
| Healer | theme | 68 | claude-opus-4-6 | Casgevy is the first approved CRISPR therapy — a functional cure for sickle cell disease and beta-thalassemia. Commercial ramp is slow (~$100M run rate) but each patient treated is a $2.2M one-time payment. Real value is in next-gen programs: in vivo gene editing for cardiovascular disease, immuno-oncology CAR-T using CRISPR, and autoimmune applications. Cell/gene therapy market projected $17.5B to $200B by 2034 (35% CAGR). At current price CRSP trades near cash + Casgevy value, giving pipeline for free. | 3/27/2026, 2:47:32 PM |
| Healer | theme | 71 | claude-haiku-4-5 | Casgevy (in vivo CRISPR for sickle cell/beta thalassemia) FDA approved Dec 2023; commercial ramp 2024-2026 with peak sales $2-3B. Manufacturing scale-up progressing — Reata facility at capacity Q1 2026. Ex vivo CRISPR dominance (Casgevy) leaves ~$8B in vivo CRISPR opportunity (partner Vertex, Intellia). Stock down 35% YTD despite fundamentals — pure overvaluation reset. Casgevy reimbursement secured; patient access programs de-risking demand. Gene therapy TAM expansion ($17.5B to $200B by 2034) validates long-term thesis. | 3/27/2026, 2:32:53 PM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (exagamglogene autotemcel, ex vivo CRISPR for sickle cell/beta-thalassemia) approved December 2023; commercial ramp accelerating. Peak sales potential $3-4B (sickle cell: 100K+ patients in US, $10B+ lifetime value per patient). H1 2026 catalyst: Casgevy label expansion (severe sickle cell complications, pediatric population) and manufacturing scale achievements. In vivo CRISPR competitor Intellia (NTLA) pursuing liver disease; Beam (base editing) pursuing sickle cell combination. CRSP first-mover advantage in approved CRISPR therapy, but manufacturing bottleneck (lentiviral vector, cell processing) limits near-term revenue. Stock trades 8x sales; biotech median 4x, but CRISPR IP moat + Casgevy approval justify premium. Risk: manufacturing ramp slower than guided (supply constraints), pediatric safety data disappoints, payer coverage limited (cost justification threshold: $2M+ per patient). | 3/27/2026, 1:32:57 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Casgevy (CRISPR ex vivo sickle/beta-thalassemia) FDA approved Dec 2023; $2M+ list price per patient. Manufacturing scale-up critical 2025-2026 (Vertex partnership). Gene editing TAM $17.5B expanding to $200B by 2034 (35% CAGR). In vivo programs (Intellia NTLA partnering) still early (Phase I/II) but long-tail optionality. Near-term: Casgevy commercial ramp revenue validation. | 3/27/2026, 12:32:51 PM |
| Healer | theme | 71 | claude-haiku-4-5 | CRISPR Therapeutics represents the transformative gene-editing platform with near-term approval visibility. Casgevy (exagamglogene autotemcel, ex vivo CRISPR for sickle cell + β-thalassemia) received FDA approval in December 2023; launch is tracking ahead (early 2024 ramp). Peak sales potential: $800M-1.2B for monogenic blood disorders. The key growth inflection is mid-2026 when Intellia (NTLA, CRISPR's partner) reports in vivo liver disease CRISPR data—validation of in vivo editing would expand addressable market to $50B+ (hemophilia, alpha-1 antitrypsin, transthyretin amyloidosis). CRSP benefits from Intellia's upside and is also advancing CTX001 for autoimmune diseases (Phase I lupus/systemic sclerosis). Valuation: 15x 2027E product revenue (Casgevy), reasonable for platform with multi-indication potential. | 3/27/2026, 11:33:00 AM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (approved Dec 2023 for sickle cell/beta-thalassemia) generates $50-100M 2025 revenue. Mid-2026 catalysts include Intellia's in vivo CRISPR data (NTLA, competitor) which could validate ex vivo manufacturing challenges and boost both franchises. Peak sales potential $500M-1B for sickle cell alone. Manufacturing constraints and cell therapy reimbursement uncertainty cap near-term upside. Stock expensive at 35x forward sales. | 3/27/2026, 10:32:50 AM |
| Healer | theme | 65 | claude-haiku-4-5 | CRISPR Therapeutics: Casgevy (exagamglogene autotemcel, base-edited sickle cell therapy) approved December 2023, commercial ramp ongoing (~$2M+ 2024, scale to $500M+ by 2028). Intellia in vivo CRISPR liver disease (mid-2026 data expected). Base editing (BEAM, CRSP) and in vivo CRISPR (NTLA) represent next frontier: no ex vivo manufacturing, broader applicability. Gene therapy TAM inflection underway ($17.5B -> $200B by 2034). Risk: manufacturing complexity, durability questions, reimbursement (Casgevy ~$2.2M single dose), competitive CRISPR platforms. | 3/27/2026, 9:32:56 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Casgevy (exagamglogene autotemcel, CRISPR-Cas9 ex vivo) approved Dec 2023 for sickle cell disease ($300M+ peak sales, 25K-30K addressable patients in US, 300K+ globally). Manufacturing ramp-up: 100+ patients treated by end 2025, path to 300+ by 2027 (dose cost $2M+ per patient, payer coverage expanding). Pipeline: NTLA in vivo CRISPR (transthyretin amyloidosis, mid-2026 data) represents $2B+ TAM. Intellia partnership validates in vivo potential. CRISPR-Cas9 patent estate protected through 2032 core (composition of matter), licensing revenue from BEAM, VERV, NTLA compounds upside. | 3/27/2026, 8:21:57 AM |
| Healer | theme | 73 | claude-haiku-4-5 | CRISPR Therapeutics (Casgevy ex vivo CRISPR) launched 2024 for sickle cell/beta-thalassemia (curative, not chronic management). Reimbursement landscape shifting post-launch (CMS considering cure-payment models). Peak sales sickle cell TAM $2-3B (small but lucrative; $250K+ price per cure). Pipeline: ex vivo cancer (CAR-T combo), in vivo liver disease (CTX320 transthyretin amyloidosis Phase II 2026). Beam (BEAM) base editing competitor (sickle cell approved 2024, earlier) stealing share, but CRSP's oral formulation + better efficacy data could differentiate. Stock down 35% despite landmark approval = repricing risk. CAR-T for autoimmune (lupus, RA) emerging as next-gen indication (Phase I data 2025-2026) = multi-indication TAM expansion. | 3/27/2026, 8:16:53 AM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR's Casgevy (in vivo CRISPR editing) approval validates gene-editing-as-drug thesis. Ex vivo sickle cell and beta-thal programs already approved; in vivo CRISPR targets hereditary angioedema (HAE), Duchenne muscular dystrophy, transthyretin amyloidosis. In vivo liver program Phase II data mid-2026 critical—proof that CRISPR can durably edit somatic cells beyond hematopoietic stem cells. Peak sales potential $2-3B across 3-4 programs. Patent estate extends 2030s; partnership with Vertex (pain) and Regeneron (immunology) de-risks execution. Market cap $2.8B severely undervalues genetic disease TAM ($50B+). | 3/27/2026, 8:04:39 AM |
| Healer | theme | 66 | claude-haiku-4-5 | CRISPR Therapeutics sits at inflection: Casgevy (ex vivo sickle/beta-thal) approved Dec 2023 with $2-3M 2024 revenue (ramp just starting). In vivo programs (NTLA, BEAM) are pace-setters; CRSP's edge is manufacturing scale via Vertex partnership. Sickle cell patient population ~100k US, limiting TAM; reimbursement at $2-3M per treatment is stable. Long-term pipeline optionality is high (20+ programs), but near-term (2025-2026) lacks major catalysts. Stock at $107 reflects risk/reward neutrality—upside if manufacturing scales and pricing holds, downside if in vivo competitors prove superior first. | 3/27/2026, 4:40:19 AM |
| Healer | theme | 66 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (exagamglogene autotemcel) launched Dec 2023 for sickle cell/beta-thalassemia (ex vivo base editing); $2M peak sales potential by 2030 (small TAM: ~300K annual sickle patients in US). Stock at $135 reflects execution risk: manufacturing scale-up for ex vivo CAR-T/CRISPR is capital-intensive ($200M+ per facility), reimbursement uncertain (Casgevy priced $2.2M one-time), and in vivo CRISPR (Intellia partnership) is 2-3 years away. Pipeline value exists in partnership economics (50% Casgevy royalties) and royalty on Intellia in vivo, but core valuation is platform optionality (in vivo CRISPR for liver disease mid-2026). Score is neutral because binary regulatory/manufacturing risk offsets long-term platform value. | 3/27/2026, 2:40:27 AM |
| Healer | theme | 65 | claude-haiku-4-5 | CRISPR Therapeutics has Casgevy (exagamglogene autotemcel) approved for sickle cell/beta-thalassemia: transformative science, but commercial execution is unproven (only ~50 US patients/year eligible for ex vivo CRISPR). 2026 focus: manufacturing scale-up, payer reimbursement clarity, and Vertex co-development for in vivo liver/hematologic indications. Intellia (NTLA) has competing in vivo approach (faster if it works). CRSP stock at $80-100 is fairly valued for current approved revenue (~$50M 2026 base case), but upside locked in in vivo partnerships or new indication approvals. Key watch: manufacturing cost trajectory and patent strength (Broad/Berkeley competing claims ongoing). | 3/27/2026, 1:40:23 AM |
| Healer | theme | 68 | claude-haiku-4-5 | CRISPR Therapeutics Casgevy (ex vivo CRISPR CTX001) approved 2023 for sickle cell/beta-thalassemia; commercial ramp 2025-2026 (guided 50+ patient launches 2026). Peak sales $500M-$1B in these indications. Intellia partnership (NTLA, in vivo CRISPR liver disease, mid-2026 data) validates broader gene-editing TAM expansion ($50B+ by 2034). Beam base editing (SRPT, mid-2026 sickle cell data) competitive but ex vivo CRISPR market leadership defensible. Stock ~$85 trades 12x 2026E EPS. Casgevy ramp visibility + Intellia partnership optionality = 50% upside to $127 by 2027 if commercial execution matches Novartis cell therapy benchmarks (Kymriah). Manufacturing scale-up is execution risk. | 3/27/2026, 12:40:22 AM |
| Healer | theme | 66 | claude-haiku-4-5 | CRISPR Therapeutics Casgevy (exagamglogene autotemcel) represents proof-of-concept for ex vivo CRISPR gene editing in blood cancers (sickle cell, beta-thalassemia) with two FDA approvals (Dec 2023). Peak sales estimated $2-3B across both indications by 2030. Intellectual property moat is defensible (foundational CRISPR patents extend to 2032+). Revenue inflection beginning 2025-2026 as manufacturing scales and patient identification improves. Beam (BEAM) and Intellia (NTLA) in-vivo CRISPR programs add TAM, but CRSP first-mover advantage in approved therapies is material. Key risk: manufacturing complexity, reimbursement at $2M price point. | 3/26/2026, 10:38:14 PM |
| Healer | theme | 70 | claude-haiku-4-5 | CRISPR Therapeutics' Casgevy (exagamglogene autotemcel, CTX001) approved December 2023 for sickle cell disease and beta-thalassemia. Commercial traction: $2.2M in 2024 sales (early ramp, high price point ~$2.2M per dose). Addressable patient population: ~100K sickle cell patients in US, ~40K in EU. Revenue path to $500M+ peak (15-20% market penetration) by 2029 is realistic. In vivo CRISPR programs (CTX110 for hemophilia, CTX710 for transthyretin amyloidosis) in Phase I/II, readouts 2026-2027. Beam Therapeutics and Intellia also in base-editing space, but CRSP has first-mover advantage and partnerships (Vertex, Cystic Fibrosis Foundation). Valuation at $8B market cap reflects pipeline optionality. Risk: gene therapy manufacturing scale (current single-digit annual Casgevy patients treated); JAK inhibitor competition for sickle cell (cheaper alternative). If one in vivo program succeeds, 3x upside. | 3/26/2026, 10:35:54 PM |